-BUZZ-China's Innovent Biologics hits all-time high on H1 growth

Innovent Biologics

26/08/2026 07:09

Adds top pct gainer in key index in third bullet, earnings details in fourth bullet
** Shares of China's Innovent Biologics 1801.HK jump 12.6% to HK$112.7, their all-time high since trading debut in October 2018
** Stock set for the biggest one-day pct gain since June 4, 2025
** Innovent is top pct gainer in benchmark Hang Seng Index .HSI, which climbs 0.7% 
** The weight loss and oncology drugmaker said its H1 revenue rose 44.8% y/y and net profit is up 50.2% y/y, as it expanded product portfolio to 20 marketed products, including new growth driver Mazdutide (GLP-1) for adult weight management and type 2 diabetes 
** Company expects continued revenue and profit growth as new products and indications are approved
** Nomura, with "Buy" rating on the stock, says Innovent's 1H26 earnings beat was driven by higher product sales 
** YTD, stock up 43.6%, Hang Seng Biotech Index .HSBIO up 15.2%
     

 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))